In a filing, Avenue Therapeutics Inc revealed its 10% Owner Davidow Robert L unloaded Company’s shares for reported $49600.0 on Dec 11 ’23. In the deal valued at $0.14 per share,353,000 shares were sold. As a result of this transaction, Davidow Robert L now holds 22,000 shares worth roughly $2640.0.
Then, Davidow Robert L sold 264,000 shares, generating $36,960 in total proceeds. Upon selling the shares at $0.14, the 10% Owner now owns 681,000 shares.
Before that, Fortress Biotech, Inc. bought 418,410 shares. Avenue Therapeutics Inc shares valued at $301,255 were divested by the 10% Owner at a price of $0.72 per share. As a result of the transaction, Fortress Biotech, Inc. now holds 1,032,390 shares, worth roughly $0.12 million.
Price Performance Review of ATXI
On Monday, Avenue Therapeutics Inc [NASDAQ:ATXI] saw its stock fall -7.75% to $0.12. Over the last five days, the stock has lost -18.57%. Avenue Therapeutics Inc shares have fallen nearly -22.36% since the year began. Nevertheless, the stocks have fallen -89.22% over the past one year. While a 52-week high of $1.28 was reached on 01/04/24, a 52-week low of $0.11 was recorded on 02/07/24. SMA at 50 days reached $0.1512, while 200 days put it at $0.4629. A total of 2.31 million shares were traded, compared to the trading of 1.22 million shares in the previous session.
Levels Of Support And Resistance For ATXI Stock
The 24-hour chart illustrates a support level at 0.1135, which if violated will result in even more drops to 0.1019. On the upside, there is a resistance level at 0.1383. A further resistance level may holdings at 0.1515. The Relative Strength Index (RSI) on the 14-day chart is 32.22, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0124, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.37%. Stochastics %K at 16.25% indicates the stock is a buying.
